Wird geladen...
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
BACKGROUND: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the seco...
Gespeichert in:
| Veröffentlicht in: | Int J Nephrol Renovasc Dis |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822864/ https://ncbi.nlm.nih.gov/pubmed/27099525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S83874 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|